Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Gastrointestinal tumours, non colorectal

2728 - Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)


21 Oct 2018


Proffered paper session - Gastrointestinal tumours, non colorectal


Clinical Research;  Immunotherapy

Tumour Site

Hepatobiliary Cancers


Michael Pishvaian


M.J. Pishvaian1, M.S. Lee2, B. Ryoo3, S. Stein4, K. Lee5, W. Verret6, J. Spahn6, H. Shao7, B. Liu6, K. Iizuka6, C. Hsu8

Author affiliations

  • 1 Oncology, Georgetown University, 20057 - Washington/US
  • 2 Unc Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill/US
  • 3 Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 4 Yale School Of Medicine, Yale University, New Haven/US
  • 5 Medical Oncology Center, Seoul National University Hospital, Seoul/KR
  • 6 Oncology, Genentech, 94080 - South San Francisco/US
  • 7 Oncology, F. Hoffmann-La Roche Ltd, Beijing/CN
  • 8 Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei/TW


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2728


Agents targeting angiogenesis or PD-L1/PD-1 signalling represent 2 types of approved treatments (tx) for HCC. In addition to its anti-angiogenic activity, bevacizumab (bev; anti-VEGF) has immunomodulatory effects that alter the tumour microenvironment, which may augment atezolizumab (atezo; anti–PD-L1)-mediated anti-tumour immune responses. This scientific rationale, including preclinical and clinical data, supports the hypothesis that the combination of atezo + bev may be effective in advanced HCC.


In a Phase Ib study cohort, patients (pts) with unresectable or metastatic HCC received atezo 1200 mg + bev 15 mg/kg IV q3w as first-line (1L) tx until loss of clinical benefit or unacceptable toxicity. The primary objectives were safety and efficacy based on investigator-assessed ORR per RECIST v1.1. Secondary endpoints included PFS and DOR per RECIST v1.1.


As of Mar 23, 2018, 68 pts were safety evaluable. Any grade (Gr) tx-related AEs occurred in 49 pts (72%). Gr 3-4 tx-related AEs were seen in 17 pts (25%), most commonly hypertension (n=8 [12%]). 5 pts (7%) experienced Gr 3 tx-related serious AEs. No tx-related Gr 5 AEs occurred. Immune-related AEs requiring systemic corticosteroid tx occurred in 4 pts (6%). As of Jul 26, 2018, 68 pts were efficacy evaluable (follow-up ≥18 wk). The ORR was 34%. Responses were observed in all clinically relevant subgroups, including pts with AFP ≥400 ng/ml, EHS and/or MVI (Table). 19 of 23 confirmed responses were ongoing (≥6 mo in 11 pts). The 6-mo PFS rate was 71%. Median DOR and median OS have not yet been reached (DOR range, 1.6+ to 22.0+). Updated data (including IRF-assessed ORR and PFS per RECIST v1.1 and HCC mRECIST) will be presented.


With a tolerable safety profile, encouraging response rates and durable responses, atezo + bev may be a promising 1L tx option for pts with advanced HCC. The Phase III IMbrave150 trial (NCT03434379) is currently recruiting.

Table: Efficacy (CCOD: Jul 26, 2018; N=68)a

Investigator-Assessed Response (confirmed per RECIST v1.1)

ORR, n/N (%)

23/68 (34%)


1/68 (1%)


22/68 (32%)

SD, n/N (%)

30/68 (44%)

DCR (CR + PR + SD), %


  16-wk DCR (CR + PR + SD ≥16 wk)


  24-wk DCR (CR + PR + SD ≥24 wk)


PD, n/N (%)

11/68 (16%)

ORR by region, n/n (%)b

  Asia (excluding Japan)

12/37 (32%)


10/30 (33%)

ORR by aetiology, n/n (%)


11/33 (33%)


10/22 (46%)


2/13 (15%)

ORR by AFP, n/n (%)c

  <400 ng/ml

12/38 (32%)

  ≥400 ng/ml

11/25 (44%)

ORR by EHS and/or MVI, n/n (%)d


18/57 (32%)


4/9 (44%)

Investigator-Assessed PFS per RECIST v1.1

Median PFS (95% CI), mo

14.9 (8.1, NE)

Range, mo

0.0+ to 23.9+

Duration of Response per RECIST v1.1

Median DOR, mo


Range, mo

1.6+ to 22.0+

a 4 patients were unevaluable. b Region data from 1 pt are missing. c Baseline AFP data from 5 pts are missing. d EHS and MVI baseline data from 2 pts are missing.

+, censored observation; AFP, a-fetoprotein; CCOD, clinical cutoff date; EHS, extrahepatic spread; MVI, microvascular invasion; NE, not estimable; NR, not reached.

Clinical trial identification


Editorial Acknowledgement

Medical writing for this abstract was provided by Steffen Biechele, PhD, of Health Interactions, Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.